Collegium Pharmaceutical Inc. (COLL) Trading Down 4%
Collegium Pharmaceutical Inc. (NASDAQ:COLL)’s share price was down 4% on Thursday . The stock traded as low as $12.12 and last traded at $12.19, with a volume of 67,697 shares changing hands. The stock had previously closed at $12.70.
Several equities analysts have weighed in on COLL shares. Zacks Investment Research downgraded shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, June 1st. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price (up previously from $28.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. Finally, Piper Jaffray Cos. reissued a “buy” rating and issued a $27.00 target price (up previously from $26.00) on shares of Collegium Pharmaceutical in a report on Thursday, June 23rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Collegium Pharmaceutical has a consensus rating of “Buy” and an average target price of $29.25.
The company’s market cap is $285.38 million. The company has a 50-day moving average of $13.00 and a 200-day moving average of $16.41.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.08. On average, analysts expect that Collegium Pharmaceutical Inc. will post ($3.25) EPS for the current fiscal year.
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.